Advertisement
Advertisement
KTTA
Pasithea Therapeutics Corp. Common Stock
0.48
USDSponsored
+0.01
+1.69%
Aug 11, 12:43 UTC -4
Open
KTTA Earnings Reports
Positive Surprise Ratio
KTTA beat 2 of 4 last estimates.
50%
Next Report
Tomorrow
Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.16
Implied change from Q1 26 (Revenue/ EPS)
--
/+33.33%
Implied change from Q2 25 (Revenue/ EPS)
--
/--
Pasithea Therapeutics Corp. Common Stock earnings per share and revenue
On May 15, 2026, KTTA reported earnings of -0.12 USD per share (EPS) for Q1 26, beating the estimate of -0.45 USD, resulting in a 73.86% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.29% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.16 USD, with revenue projected to reach -- USD, implying an increase of 33.33% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Passage Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$2.69
Actual
-$2.44
Surprise
+9.62%
Imunon, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.94
Actual
-$0.54
Surprise
+42.83%
Axsome Therapeutics, Inc
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.86
Actual
-$0.99
Surprise
-14.90%
Apogee Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.13
Surprise
-4.39%
Legend Biotech Corporation - ADR
Report Date
Aug 11, 2026 For Q2 26
Estimate
$0.07
Actual
$0.09
Surprise
+17.80%
Alamar Biosciences, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.22
Surprise
+33.83%
Bicara Therapeutics Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.84
Actual
-$0.82
Surprise
+3.18%
Septerna, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.28
Surprise
+33.26%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.55
Actual
-$0.61
Surprise
-9.83%
Autolus Therapeutics plc - ADR
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.22
Actual
-$0.15
Surprise
+31.82%
FAQ
What were Pasithea Therapeutics Corp. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Pasithea Therapeutics Corp. Common Stock reported EPS of -$0.12, beating estimates by 73.86%, and revenue of $0.00, 0% as expectations.
How did the market react to Pasithea Therapeutics Corp. Common Stock's Q1 2026 earnings?
The stock price moved down -1.29%, changed from $0.78 before the earnings release to $0.77 the day after.
When is Pasithea Therapeutics Corp. Common Stock expected to report next?
The next earning report is scheduled for Aug 12, 2026.
What are the forecasts for Pasithea Therapeutics Corp. Common Stock's next earnings report?
Based on --
analysts, Pasithea Therapeutics Corp. Common Stock is expected to report EPS of -$0.16 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement